GSK outlines rare disease strategy
This article was originally published in Scrip
Executive Summary
Having announced back in February that it was establishing a specific business unit to build a rare diseases franchise, GlaxoSmithKline is beginning to reveal what its focus and approach will be. Dr Shelagh Wilson, vice-president of business development, GSK Rare Diseases, spoke exclusively to Scrip following her presentation at BioPartnering Europe in London this week.